Revolution Medicines

RVMD Q3 2025 Earnings

Reported Nov 5, 2025 at 4:00 PM ET · SEC Source

Q3 25 EPS

$-1.61

MISS 14.25%

Est. $-1.41

Q3 25 Revenue

N/A

Est. $1.6M

vs S&P Since Q3 25

+123.5%

BEATING MARKET

RVMD +131.0% vs S&P +7.5%

Market Reaction

Did RVMD Beat Earnings? Q3 2025 Results

Revolution Medicines delivered a steeper-than-expected loss in Q3 2025, missing Wall Street estimates as the clinical-stage oncology company accelerates spending across its RAS(ON) inhibitor pipeline. The company posted a loss of $1.61 per share, fal… Read more Revolution Medicines delivered a steeper-than-expected loss in Q3 2025, missing Wall Street estimates as the clinical-stage oncology company accelerates spending across its RAS(ON) inhibitor pipeline. The company posted a loss of $1.61 per share, falling short of the $-1.41 consensus by 14.25%, with no product revenue given its pre-commercial status. The primary driver was a near-doubling of R&D expenses to $262.51 million, reflecting expanded late-stage trial activity and manufacturing costs for daraxonrasib, zoldonrasib, and elironrasib, while G&A expenses more than doubled to $52.76 million as the company builds out commercial infrastructure. The net loss widened to $305.21 million from $156.29 million a year ago. Despite the shortfall, Revolution Medicines maintained full-year 2025 net loss guidance of $1.03 billion to $1.09 billion and enters 2026 with $1.93 billion in liquidity, key data readouts expected from the RASolute 302 trial, and plans to initiate a registrational zoldonrasib combination study in first-line PDAC in the first half of next year.

Key Takeaways

  • Increased R&D spending driven by expanded clinical trial activity and manufacturing for daraxonrasib, zoldonrasib, and elironrasib
  • Higher G&A expenses from commercial preparation activities and headcount growth
  • Royalty Pharma partnership providing capital with $250 million first tranche received in June 2025
24/7 Wall St

RVMD YoY Financials

Q3 2025 vs Q3 2024, source: SEC Filings

“Our diverse clinical and preclinical RAS(ON) inhibitor programs continue to make encouraging progress and deliver on important milestones. Backed by robust operational capabilities and a strong financial position, we feel growing momentum in support of our goal to establish new global standards of care for people living with RAS-addicted cancers, including pancreatic, lung and colorectal cancers.”

— Mark A. Goldsmith, Q3 2025 Earnings Press Release